Bausch Health Companies Inc.

BHCSEC EDGAR

Pharmaceutical Preparations(NJ)CIK: 885590

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$8.8B	$8.1B	$8.4B	$8.0B	$8.6B
Cost of Goods Sold (Deprecated 2018-01-31)	—	—	—	—	—
Selling, General and Administrative Expense	$2.9B	$2.6B	$2.6B	$2.4B	$2.6B
Operating Income (Loss)	$963.0M	$454.0M	$450.0M	$676.0M	-$203.0M
Other Nonoperating Income (Expense)	-$28.0M	-$35.0M	-$373.0M	-$502.0M	-$1.4B
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$390.0M	-$129.0M	-$1.0B	-$934.0M	-$1.8B
Income Tax Expense (Benefit)	$221.0M	$83.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$26.5B	$27.4B	$25.7B	$29.2B	$31.2B
Assets, Current	$5.8B	$5.6B	$4.2B	$5.6B	$5.3B
Cash and Cash Equivalents, at Carrying Value	$947.0M	$564.0M	$582.0M	$605.0M	$3.2B
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Inventory, Net	$1.6B	$1.5B	$1.1B	$993.0M	$1.1B
Liabilities	$26.8B	$27.4B	$25.4B	$29.2B	$30.6B
Liabilities, Current	$6.8B	$4.3B	$3.9B	$5.2B	$4.9B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$1.0B	-$728.0M	$1.4B	$1.1B	$1.5B
Net Cash Provided by (Used in) Investing Activities	-$2.1B	-$303.0M	$409.0M	-$261.0M	-$419.0M
Net Cash Provided by (Used in) Financing Activities	$1.5B	-$474.0M	-$1.5B	-$2.3B	$1.4B
Payments to Acquire Property, Plant, and Equipment	$215.0M	$218.0M	$269.0M	$302.0M	$270.0M
Payments of Ordinary Dividends, Common Stock	—	—	—	—	—
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)